Research Grants
ANNUAL
REPORT 2024
Research Grants
ANNUAL
REPORT 2024
ANNUAL REPORT 2024
Research Grants
Infrastructure Funding
Australian Government Cancer Australia Support for Cancer Clinical Trials Grant: 1 January 2022 to 30 June 2024, AUD$1,250,000 awarded to ANZUP. During this reporting period ANZUP received AUD$395,000 and is reported in the Annual Accounts.
Research Grants
Funds provided by, the National Health and Medical Research Council, philanthropic funding bodies and pharmaceutical companies in support of ANZUP trials managed by the University of Sydney or other administering institution, are not reported in ANZUP’s financial accounts. Funds to support ANZUP sponsored trials and site payments, insurance and other trial related costs are transferred to ANZUP and are reflected in these accounts.
ANZUP grant income and expenditure during this reporting period are included in the 2023/2024 financial accounts. Grants awarded to ANZUP Cancer Trials Group during this reporting period are listed below:
ANZadapt: Phase II randomised controlled trial of patient-specific adaptive versus continuous Abiraterone or eNZalutamide in metastatic castration-resistant prostate cancer. Funding by ACF (Anti Cancer Foundation) EUR$647,498. During this reporting period $150,000 was transferred to ANZUP and reported in the annual accounts.
BCGMM: Adding mitomycin to BCG as adjuvant intravesical therapy for high-risk, non–muscle-invasive bladder cancer: a 2-stage, randomised phase 3 trial. Funding by NHMRC AUD$1,587,163.80. (2019 – 2023). No funds were transferred to ANZUP in this period.
CLIMATE: Assessing the Clinical utility of miR-371a-3p as a marker of residual disease in Clinical Stage 1 Testicular Germ Cell Tumour, following orchidectomy. Funding by Ben Tran AUD$150,000, ANZUP Below the Belt 2019 AUD$50,000 and ANZUP Discretionary Funding AUD$250,000. During this reporting period AUD$62,000 was transferred to ANZUP and reported in the annual accounts.
DASL-HiCaP: A randomised phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localised prostate cancer. Funding by Bayer USD$53,173,088. During this period USD$335,000 was transferred to ANZUP and reported in the annual accounts.
ENZAMET: A randomised phase III trial of Enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer. Funding by Astellas AUD$19,962,490 (2014-2022). During this reporting period AUD$1,000 and USD$95,142 was transferred to ANZUP and was reported in the annual accounts.
ENZAMET Translational Research Program: During this reporting period AUD$277,737.65 and USD$1,769,209.64 was transferred to ANZUP for TR Execution Milestone Direct Costs and was reported in the annual accounts.
ENZA-p: A randomised phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration resistant prostate cancer treated with enzalutamide. Funding by Prostate Cancer Research Alliance: The Australian Government and Movember Foundation Collaboration AUD$4,000,000; Endocyte USD$320,000; St Vincent’s Clinic Foundation AUD$400,000; GenesisCare AUD$300,000; and Roy Morgan Research Ltd AUD$300,000; (2020-2024). During this reporting period no funds was transferred to ANZUP and was reported in the annual accounts.
ENZARAD: A randomised phase III trial of Enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised prostate cancer. Funding by Astellas AUD$13,184,412(2014-2022). During this reporting period no funds were transferred to ANZUP.
EVOLUTION: A randomised phase II trial of Radionuclide 177Lu-PSMA Therapy versus 177Lu-PSMA in Combination with Ipilimumab and Nivolumab for Men with Metastatic Castration Resistant Prostate Cancer (mCRPC). Funding by Prostate Cancer Foundation of Australia AUD$1,500,000; Bristol Myers Squibb USD$1,296,698, Novartis USD$320,000, (2021-2024). During this reporting period ANZUP received AUD$400,000and USD$642,140.76 and is reported in the annual accounts.
Geni-AIRSPACE: A three-part, sequential, multi-centre, open label randomised controlled trial (1:1) of risk stratification by three molecular tests to inform decision-making in people with clinically localised FIR CaP. During this reporting period AUD$200,000 was transferred to ANZUP and was reported in the annual accounts.
GUIDE: A randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care (SOC) docetaxel in metastatic castration-resistant prostate cancer (mCRPC). Funding by Chris O’Brien Lifehouse Philanthropic AUD$450,000, ANZUP Belt the Belt Research Fund AUD$50,000 and ANZUP discretionary funding AUD$350,000. During this reporting period AUD$70,000 was transferred to ANZUP and was reported in the annual accounts.
KEYPAD: A phase II trial using denosumab and pembrolizumab in clear cell renal carcinoma. Funding by Merck Sharpe Dohme and Amgen AUD$2,454,925. During this reporting period ANZUP received no funds reported in the annual accounts.
PCR-MIB: Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer. During this reporting period AUD$109,270.16 and AUD$331,978.18 for Translational Research was transferred to ANZUP and was reported in the annual accounts.
PET-MET: Retrospective analysis of the ENZAMET cohort – Utility of PSMA PET scan quantitation and CT radiomics as prognostic and predictive biomarkers. Funding by Astellas AUD$550,000. During this reporting period ANZUP received AUD$50,000 and is reported in the annual accounts.
RAMPART: Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART) An international investigator-led phase III multi-arm multi-stage multi-centre randomised controlled platform trial of adjuvant therapy in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse. Funding by UCL AUD$2,080,000. During this reporting period ANZUP received USD$80,000 and is reported in the annual accounts.
TIGER: A Randomised Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilising Paclitaxel plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumours (ANZUP 1604). Funding received from the Movember Foundation was $454,803.74. No funds were received in this reporting period.
UNISON: Phase II sequential cohort trial of Single Agent Nivolumab, then Combination Ipilimumab + Nivolumab in metastatic or unresectable non-clear cell renal cell carcinoma (ANZUP 1602). Bristol Myers Squibb (BMS) provided funding USD$1,681,822 and product to support the UNISoN trial. During this reporting period ANZUP received no funds reported in the annual accounts.
UNICAB: A phase II trial of single agent cabozantinib in patients with locally advanced or metastatic non-clear cell renal cell carcinoma post immunotherapy or who are unsuitable for immunotherapy (ANZUP 1801). AUD$120,000 was received in this reporting period.